Search for: "EISAI, INC."
Results 1 - 20
of 93
Sort by Relevance
|
Sort by Date
29 Feb 2024, 5:17 pm
On June 27, 2023, the PTO issued two ORDER TO SHOW CAUSE letters (here and here) to Gilead Sciences Inc. [read post]
8 Jan 2023, 1:00 pm
Food and Drug Administration gave accelerated approval to the Alzheimer’s drug lecanemab, developed by Eisai Co. and Biogen Inc. [read post]
30 Nov 2022, 12:00 pm
A phase III clinical trial that published results earlier this week in the New England Journal of Medicine shows promising data that Alzheimer’s drug, Lecanemab by Eisai and Biogen Inc, can slow cognitive decline. [read post]
17 Oct 2022, 12:00 pm
Biogen Inc. and Eisai Co. have partnered together on experimental drug, lecanemab, which they say significantly slowed symptoms of Alzheimer’s. [read post]
25 Oct 2021, 7:36 am
The defendants in the Belviq lawsuits, Arena Pharmaceuticals and Eisai, Inc., have recently filed motions to dismiss in many of these cases. [read post]
25 Oct 2021, 7:36 am
The defendants in the Belviq lawsuits, Arena Pharmaceuticals and Eisai, Inc., have recently filed motions to dismiss in many of these cases. [read post]
7 Apr 2021, 1:20 pm
This Belviq recall has resulted in Belviq lawsuits being filed against the responsible pharmaceutical company, Eisai Inc. [read post]
4 Feb 2021, 8:31 am
In response to the FDA safety announcement for Belviq, Easai Inc. agreed to voluntarily withdraw the drug from the market. [read post]
15 May 2020, 11:48 am
As according to the responsible drug company, Eisai, Inc., on its Belviq.com website: BELVIQ was approved in June 2012 by the FDA as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related co-morbid condition, and was launched in the United States in June 2013. [read post]
10 May 2020, 9:24 am
Another Japanese drug company, Eisai, Inc., purchased Arena’s worldwide rights to make and market Belviq in 2017. [read post]
5 May 2020, 1:37 pm
How To Know if Belviq Injured You In February 2020, pharmaceutical manufacturer Eisai, Inc. withdrew its weight-management drug Belviq (generic name lorcaserin) from the U.S. market at the request of the United States Food and Drug Administration (FDA) after a clinical trial identified an increased occurrence of cancer in people who took it. [read post]
9 Mar 2020, 7:46 am
Eisai Inc. had the exclusive right to market and distribute lorcaserin in the United States since 2012 and took over complete control of the drug, including regulatory compliance and safety monitoring, in 2017. [read post]
9 Mar 2020, 7:46 am
Eisai Inc. had the exclusive right to market and distribute lorcaserin in the United States since 2012 and took over complete control of the drug, including regulatory compliance and safety monitoring, in 2017. [read post]
14 Feb 2020, 5:23 am
Excess Cases Of Pancreatic Cancer, Colon Cancer, Rectal Cancer, And Lung Cancer Observed In Belviq Safety Clinical Trial (Posted by Tom Lamb at DrugInjuryWatch.com) On February 13, 2020 the FDA requested Eisai Inc. to voluntarily withdraw its diet drug Belviq because a Belviq safety clinical trial shows an increased occurrence of cancer cases. [read post]
14 Jan 2020, 1:24 pm
Some additional contextual information is provided by this FDA document, "Safety clinical trial shows possible increased risk of cancer with weight-loss medicine Belviq, Belviq XR (lorcaserin)": When approving [Belviq], we required the drug manufacturer, Eisai Inc., to conduct a randomized, double-blind, placebo-controlled clinical trial to evaluate the risk of heart-related problems. [read post]
24 Jan 2019, 4:00 pm
In IQVIA RDS Inc. v. [read post]
26 Sep 2017, 2:00 pm
Eisai Inc. announced this week it had signed a 40,000-square-foot ... [read post]
22 Aug 2016, 6:48 pm
Eisai-- who dismissed the Relator's FCA claims due to her failure to satisfy Rule 9(b): U.S. ex rel Jallali v. [read post]
22 Aug 2016, 6:48 pm
Eisai-- who dismissed the Relator's FCA claims due to her failure to satisfy Rule 9(b): U.S. ex rel Jallali v. [read post]
18 Jul 2016, 7:26 am
Eisai, Inc. v. [read post]
